Inion's BioRestore glass fibre bone graft substitute:
This article was originally published in Clinica
Executive Summary
Finnish firm Inion has received 510(k) clearance from the US FDA for its BioRestore bone graft substitute. The product, made from bioactive glass fibres, is designed to fill bony voids resulting from surgery or traumatic injury. The implant accelerates the formation of new bone, while gradually degrading over six months to allow the bone to fill the void. BioRestore is now approved for use in dental and cranio-maxillofacial applications, but is also being reviewed by the FDA for use in orthopaedic trauma indications. The US market for synthetic bone graft substitutes is estimated at around $158m, claimed the Tampere firm. Inion hopes to gain CE-marking for BioRestore during the second half of 2007 and plans to launch the product in Europe soon after.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.